Safety and preliminary efficacy data of a novel Casein Kinase 2 (CK2) peptide inhibitor administered intralesionally at four dose levels in patients with cervical malignancies

Solares, Ana M; Santana, Agueda; Baladrón, Idania; Valenzuela, Carmen; González, Carlos A; Díaz, Alina; Castillo, Dagnelia; Ramos, Thelvia; Gómez, Roberto; Alonso, Daniel F; Herrera, Luis.
BMC Cancer ; 9May 13, 2009. tab
Artículo en Inglés | CUMED | ID: cum-39785

Documentos relacionados

  1. Safety and preliminary efficacy data of a novel casein kinase 2 (CK2) peptide inhibitor administered intralesionally at four dose levels in patients with cervical malignancies.
  2. New responsibilities for aged kinases in B-lymphomas.
  3. Preliminary stop of the TOPical Imiquimod treatment of high-grade Cervical intraepithelial neoplasia (TOPIC) trial.
  4. Self-Administration of Long-Acting Somatostatin Analogues in NET Patients-Does It Affect the Clinical Outcome?
  5. Clinical efficacy of a new therapeutic option for lower genital tract lesions: 5-ALA photodynamic therapy.
  6. A preliminary study for the treatment of cervical colposcopic lesions with the biological compound AV2.
  7. Development of a goat model for evaluation of withaferin A: Cervical implants for the treatment of cervical intraepithelial neoplasia.
  8. Photodetection and Safety of 5-Aminolevulinic Acid-Induced Porphyrin in Patients With Cervical Intraepithelial Neoplasia.
  9. TOPical Imiquimod treatment of residual or recurrent cervical intraepithelial neoplasia (TOPIC-2 trial): a study protocol for a randomized controlled trial.
  10. Pituitary apoplexy in endocrinologically silent adenoma during somatostatin analog administration for pancreatic neuroendocrine tumor: A case report.